title: TIMP-2 mutant decreases MMP-2 activity and augments pressure overload induced LV dysfunction and heart failure.
abstract: Pressure overload induces cardiac extracellular matrix (ECM) remodelling and results in heart failure. ECM remodelling by matrix metalloproteinases (MMPs) is primarily regulated by their target inhibitors, tissue inhibitor of matrix metalloproteinases (TIMPs). It is known that TIMP-2 is highly expressed in myocardium and is required for cell surface activation of pro-MMP-2. We and others have reported that imbalance between angiogenic growth factors and anti-angiogenic factors results in transition from compensatory cardiac hypertrophy to heart failure. We previously reported the pro-angiogenic role of MMP-2 in cardiac compensation, however, the specific role of TIMP-2 during pressure overload is yet unclear. We hypothesize that genetic ablation of TIMP-2 exacerbates the adverse cardiac matrix remodelling due to lack of pro-angiogenic MMP-2 and increase in anti-angiogenic factors during pressure overload stress and results in severe heart failure. To verify this, ascending aortic banding (AB) was created to mimic pressure overload, in wild type C57BL6/J and TIMP-2-/- (model of MMP-2 deficiency) mice. Left ventricular (LV) function assessed by echocardiography and pressure-volume loop studies showed severe LV dysfunction in TIMP-2-/- AB mice compared to controls. Expression of MMP-2, vascular endothelial growth factor (VEGF) was decreased and expression of MMP-9, anti-angiogenic factors endostatin and angiostatin was increased in TIMP-2-/- AB mice compared with wild type AB mice. Connexins (Cx) are the gap junction proteins that are widely present in the myocardium and play an important role in endothelial-myocyte coupling. Our results showed that expression of Cx 37 and 43 was decreased in TIMP-2-/- AB mice compared with corresponding wild type controls. These results suggest that genetic ablation of TIMP-2 decrease the expression of pro-angiogenic MMP-2, VEGF and increases anti-angiogenic factors that results in exacerbated abnormal ventricular remodelling leading to severe heart failure.
authors: Department of Physiology and Biophysics, University of Louisville School of Medicine, Louisville, KY 40202, USA. s0givv01@louisville.edu
authors: S
authors: S
authors: Givvimani
authors: S
authors: S
authors: Kundu
authors: N
authors: N
authors: Narayanan
authors: F
authors: F
authors: Armaghan
authors: N
authors: N
authors: Qipshidze
authors: S
authors: S
authors: Pushpakumar
authors: T P
authors: TP
authors: Vacek
authors: S C
authors: SC
authors: Tyagi
mesh_terms: D020533:Angiogenesis Inhibitors; D000818:Animals; D001011:Aorta; D006332:Cardiomegaly; D018031:Connexin 43 / Q000235:genetics; D017630:Connexins / Q000235:genetics; D003250:Constriction; D005109:Extracellular Matrix / Q000502:physiology; D015870:Gene Expression; D006333:Heart Failure / Q000209:etiology* / Q000503:physiopathology; D006973:Hypertension / Q000150:complications* / Q000209:etiology; D017379:Hypertrophy, Left Ventricular; D008297:Male; D020778:Matrix Metalloproteinase 2 / Q000172:deficiency* / Q000235:genetics / Q000502:physiology; D051379:Mice; D008810:Mice, Inbred C57BL; D018345:Mice, Knockout; D009206:Myocardium / Q000648:ultrastructure; D018919:Neovascularization, Physiologic / Q000502:physiology; D019716:Tissue Inhibitor of Metalloproteinase-2 / Q000172:deficiency* / Q000502:physiology; D042461:Vascular Endothelial Growth Factor A / Q000235:genetics / Q000378:metabolism; D018487:Ventricular Dysfunction, Left / Q000209:etiology*; D020257:Ventricular Remodeling / Q000502:physiology; D000097006:Gap Junction alpha-4 Protein
chemical_list: D020533:Angiogenesis Inhibitors; D018031:Connexin 43; D017630:Connexins; D020778:Matrix Metalloproteinase 2; D019716:Tissue Inhibitor of Metalloproteinase-2; D042461:Vascular Endothelial Growth Factor A; D000097006:Gap Junction alpha-4 Protein
references: Dev Dyn. 1997 Jul;209(3):261-8
references: 9215641
references: J Mol Cell Cardiol. 2001 Feb;33(2):359-71
references: 11162139
references: J Biol Chem. 1998 Jan 9;273(2):871-80
references: 9422744
references: Dev Biol. 1999 Aug 15;212(2):255-63
references: 10433819
references: Arch Physiol Biochem. 2010 May;116(2):63-72
references: 20230216
references: Biochim Biophys Acta. 2010 Jan;1803(1):55-71
references: 20080133
references: Lab Anim Sci. 1993 Apr;43(2):189-92
references: 8320967
references: Circulation. 2010 Sep 7;122(10):993-1003
references: 20733099
references: J Appl Physiol (1985). 2011 Apr;110(4):1093-100
references: 21233344
references: Circulation. 2006 May 23;113(20):2435-44
references: 16702468
references: Circulation. 2005 Aug 23;112(8):1136-44
references: 16103240
references: Clin Transl Sci. 2011 Feb;4(1):24-31
references: 21348952
references: J Biol Chem. 1995 Mar 10;270(10):5331-8
references: 7890645
references: FEBS Lett. 2004 Apr 9;563(1-3):129-34
references: 15063736
references: Am J Physiol Cell Physiol. 2012 Jul 1;303(1):C41-51
references: 22517358
references: Thromb Haemost. 2005 Feb;93(2):212-9
references: 15711735
references: Circulation. 2011 Nov 8;124(19):2094-105
references: 21986284
references: J Clin Invest. 2000 Jul;106(1):55-62
references: 10880048
references: Annu Rev Physiol. 2003;65:45-79
references: 12524460
references: Int J Physiol Pathophysiol Pharmacol. 2011;3(2):107-19
references: 21760969
references: PLoS One. 2012;7(3):e32388
references: 22479323
references: Echocardiography. 2007 Jan;24(1):83-9
references: 17214630
references: Circ Res. 2010 Mar 5;106(4):796-808
references: 20056917
references: Basic Res Cardiol. 2008 Jul;103(4):319-27
references: 18347835
references: Am J Physiol Heart Circ Physiol. 2009 Feb;296(2):H428-34
references: 19074676
references: J Biol Chem. 2000 Aug 25;275(34):26411-5
references: 10827175
references: Circ Arrhythm Electrophysiol. 2012 Apr;5(2):380-90
references: 22368123
references: Physiol Rev. 2007 Oct;87(4):1285-342
references: 17928585
references: FEBS Lett. 1996 Sep 9;393(1):101-4
references: 8804434